NYSE:ZTSPharmaceuticals
Zoetis (ZTS) Valuation Check After Earnings Beat Guidance Upgrade And Fresh Institutional Buying
Zoetis (ZTS) is back in focus after reporting quarterly and full year 2025 results that came in ahead of analyst expectations, along with 2026 guidance and fresh institutional buying interest.
See our latest analysis for Zoetis.
Despite the strong 2025 earnings update, recent trading has been subdued. A 7.24% 90 day share price return contrasts with a 1 year total shareholder return decline of 18.59%, suggesting longer term sentiment has been weaker even as shorter term momentum has picked...